FDA, Rival Sanofi hit Merck RSV for babies to Astrazeneca

Approved food and drug setting on Monday Merck ‘s struck get rid of In the first season of the virus, the respiration brings a rival to a similar treatment from the sinus Sanofi and Astrazeneca.

This decision The company’s DSV season will usually allow the RSV season that occurs around the fall and winter and to start a drug to be sold as Enflonsia. Merck said the shot was waiting for shooting commands to start in July and said he was broadcast before the delivery of the virus.

Approved doctors give a new choice to touch the virus that caused thousands of deaths between older Americans and hundreds of deaths each year. The consequences of RSV are the reason for hospitalization among newborns.

“We are eager to ensure the existence of the United States (Enflonsia) in the United States (Enflonsia) to help us significantly download the widespread seasonal infection in families and health systems.” Dean Li said the president of Merck Research Laboratories was released.

Merkk’s shot, due to unprecedented requests, the 2023 RSV season will compete against a similar blockbuster in the national supply and AstraZeneca.

Both are preventive monoclonal antibodies directly delivered antibodies to ensure immediate protection. However, each aims to a different part of the virus, has difficulty comparing them directly.

Merck’s shot can be taken to babies, regardless of their weight, which can offer comfort in terms of the company’s dose. Meanwhile, the recommended dose of Beyfortus is based on the baby’s body weight.

Monday Sanofi obvious To increase the supply of beyfortus, aggressive effort, including the stroke in the third quarter, the plan to start sending earlier. Last year, Beyfortus ordered the sale of 1.7 billion euros ($ 1.8 billion).

Vaccines for RSV are available in the United States as well as companies Pfizer, GSK and Modern. However, these shots are for use only in adults or pregnant women. Recently FDA Stopped the test RSV footage in young children when evaluating security concerns.

All of the market companies are preparing recommendations for RSV shootings and other immunizations, June 25-27 – June 25-27 to June 25-27 on June 27 to June 27, a meeting of vaccine centers.

In a staged test until the end of Enflonsia, the shot was taken to hospital with more than 84%, and in 5 months in 5 months in 5 months in 5 months in 5 months in 5 months in 5 months. At the same time, at the same time, medical care has reduced lower respiratory infections that require more than 60% of more than 60% compared to a placebo in five months.

RSV is a common cause of low respiratory infections such as pneumonia.